Theravance Biopharma (TBPH) EBIT Margin Growth (5y) (2018 - 2026)
Theravance Biopharma (TBPH) EBIT Margin Growth (5y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53,485.00 |
| Dec 31, 2025 | 45,199.00 |
| Sep 30, 2025 | 38,736.00 |
| Jun 30, 2025 | 47,051.00 |
| Mar 31, 2025 | 27,110.00 |
| Dec 31, 2024 | -1,965.00 |
| Sep 30, 2024 | 46,043.00 |
| Jun 30, 2024 | -3,150.00 |
| Mar 31, 2024 | 130,276.00 |
| Dec 31, 2023 | 36,240.00 |
| Sep 30, 2023 | 43,063.00 |
| Jun 30, 2023 | 9,020.00 |
| Mar 31, 2023 | 54,191.00 |
| Dec 31, 2022 | 163,462.00 |
| Sep 30, 2022 | 125,982.00 |
| Jun 30, 2022 | 161,258.00 |
| Mar 31, 2022 | 161,393.00 |
| Dec 31, 2021 | 64,026.00 |
| Sep 30, 2021 | -23,077.00 |
| Jun 30, 2021 | -17,979.00 |